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Broadly neutralizing antibodies (bNAb) that target a
conserved region of a viral antigen hold significant
therapeutic promise. CR8020 is a bNAb that targets
the stem region of influenza A virus (IAV) hemag-
glutinin (HA). CR8020 is currently being evaluated
for prophylactic use against group 2 IAVs in phase
II studies. Structural and computational analyses
reported here indicate that CR8020 targets HA resi-
dues that are prone to antigenic drift and host selec-
tion pressure. Critically, CR8020 escape mutation is
seen in certain H7N9 viruses from recent outbreaks.
Furthermore, the ability of the bNAb Fc region to
effectively engage activating Fcg receptors (FCgR)
is essential for antibody efficacy. In this regard,
our data indicate that the membrane could sterically
hinder the formation of HA-CR8020-FcgRIIa/HA-
IgG-FcgRIIIa ternary complexes. Altogether, our
analyses suggest that epitope mutability and acces-
sibility to immune complex assembly are important
attributes to consider when evaluating bNAb candi-
dates for clinical development.
INTRODUCTION
Recently, technologies related to the characterization and isola-
tion of B cells from infected or vaccinated individuals have iden-
tified broadly neutralizing antibodies (bNAbs) targeting highly
diverse pathogens, such as HIV (Zwick et al., 2003; Wu et al.,
2010; Scheid et al., 2011; Pejchal et al., 2010, 2011; Zwick
et al., 2001) and influenza (Ekiert et al., 2011; Sui et al., 2009;
Dreyfus et al., 2013; Corti et al., 2011). Analysis of these anti-
bodies, including the epitopes they target and their germline of
origin, provides information useful to vaccine design (Kwong
et al., 2011; Nabel, 2012; Steel et al., 2010). In addition, in the
absence of the development of a universal, broadly protective
vaccine strategy for viral diseases such as influenza, passive
immunization with antibodies could help treat the disease and
protect so-called ‘‘at risk’’ populations, such as the immuno-
compromised and elderly individuals. Although early bNAbs for644 Cell Host & Microbe 15, 644–651, May 14, 2014 ª2014 Elsevier IHIV, such as 2F5 (Muster et al., 1993) and 4E10 (Zwick et al.,
2001), exhibited polyreactivity and unusually short half-lives in
phase I trials, passive immunization for influenza and HIV has
progressed to the point that multiple antibodies are now entering
human clinical trials.
In the case of influenza, efforts weremade in the past to isolate
cross-reactive bNAbs targeting the conserved, relatively immu-
nologically subdominant epitopes of the virus (Graves et al.,
1983; Okuno et al., 1993). With advances in technologies, the
recent years have seen a tremendous surge in the development
of bNAbs against the hemagglutinin (HA) protein of influenza A
virus (IAV) (Ekiert et al., 2011; Sui et al., 2009; Dreyfus et al.,
2013; Corti et al., 2011). The applicability of such bNAbs in a pro-
phylactic setting is being evaluated for CR8020 (Ekiert et al.,
2011), which targets group 2 IAVs. Currently, CR8020 is evalu-
ated both as a single agent (NCT01938352) and in combination
with a group 1 bANb-CR6261 (NCT01992276) in two separate
phase II studies. In these studies, the prophylactic potential of
CR8020 is being evaluated in individuals who are challenged
with a group 2 H3N2 virus. Presently, CR8020 is the most
advanced anti-group 2 bNAb undergoing clinical trials. The
H3N2 subtype has been circulating in humans since 1968,
causing more than 400,000 deaths in the United States alone
(Kawaoka et al., 1989; Jansen et al., 2007; Iwane et al., 2004).
Besides H3N2, another group 2 subtype, the avian-origin
H7N9, recently led to 144 cases of infection in China (Gao
et al., 2013). Of these cases, 46 died (>30% mortality), raising
concerns that the virus might change into a form that is more
transmissible in humans. More troubling is the fact that the
recent H7N9 strains are resistant to M2 channel blockers, and
some strains are also displaying resistance to Tamiflu and Re-
lenza (Hai et al., 2013). In light of the above, an understanding
of the biological activity of CR8020, as well as clinical consider-
ations, particularly against group 2 subtypes H3N2 and H7N9,
becomes extremely important.
RESULTS
CR8020 Binding Residues on HA Are Susceptible to
Sequence Drift and Potential for Escape Mutations
CR8020 targets an immune subdominant, relatively conserved,
membrane-proximal stem region of HA, thus preventing fusion
and viral entry through (1) inhibiting fusogenic conformational
change and/or (2) inhibiting cleavage of HA0 by host proteases.nc.
Table 1. Analysis of CR8020 Epitope Conservation in 3,794 Human, Avian, and Swine A/H3N2 HA Sequences
HA2 Position
(H3 Numbering) Consensus Alignment Details
Number of
Sequences
SIN
Score
Predicted Escape
Mutations
15 Glu Glu = 3,793, Lys = 1 3,794 0.1596 A
16 Gly Gly = 3,794 3,794 0 V > E > A
19 Asp Asn = 39, Asp = 3,753, Glu = 1, Gly = 1 3,794 0.1171
25 Arg Arg = 3,794 3,794 0.5316
30 Glu Glu = 3,793, Val = 1 3,794 0.1586 A > D
32 Thr Arg = 1,325, Ile = 530, Met = 13, Thr = 1,923, Val = 3 3,794 0.0904
33 Gly Glu = 3, Gly = 3791 3,794 0 V > A > R
34 Gln Gln = 3,794 3,794 0.4111
35 Ala Ala = 3,784, Val = 10 3,794 0.0656 S
36 Ala Ala = 3794 3,794 0.0672 S
38 Leu Arg = 1, Ile = 17, Leu = 3,764, Phe = 12 3,794 0.1189
146 Asn Asn = 3,792, Asp = 1, Val = 1 3,794 0.2075
150 Gly Arg = 1, Asp = 6, Gln = 1, Glu = 275, Gly = 3,509, Lys = 1, Val = 1 3,794 0.2677
At each site, the predicted escape mutations are ranked (>) according to difference in free energy of binding. Mutation potential was measured by
applying SIN analysis on the crystal structure of A/X-31 (H3N2) H3 (PDB ID: 1HGG).
Cell Host & Microbe
CR8020 HA-Stem Epitope Can Accrue Escape MutationsInterestingly, Ekiert et al. (2011) identified two CR8020 escape
mutations—D19N and G33E in HA2 domain—which also occur
in select natural H3 strains. In their study, the antibody was found
to be less sensitive to other epitope changes observed in natu-
rally occurring H3N2 strains. To identify the potential for escape
mutations that are not readily observed in nature, we applied our
computational approach based on atomic interaction networks
in order to examine the relationship between amino acids within
the epitope and evaluate the mutability of the individual sites. A
detailed description of the atomic interaction network approach,
called Significant Interactions Network (SIN), can be found else-
where (Soundararajan et al., 2011). A brief description of the
network approach can be found in the Experimental Procedures.
Previously, we applied this approach to successfully demon-
strate how immunologic pressure-induced antigenic changes
on the globular head region of A/Puerto Rico/8/1934 (PR8)
H1N1 IAV can affect host receptor binding affinity through inter-
residue interactions (Soundararajan et al., 2011). From sequence
analyses, 9 out of 13 CR8020 epitope sites have seen amino acid
variation (Experimental Procedures). Furthermore, SIN scores
suggest that only four sites—R25, Q34, N146, and G150—are
undermutational constraints (SIN > 0.2), suggesting the potential
for antiviral-associated escape mutations (Experimental Proce-
dures and Table 1). Using the cocrystal structure of CR8020
Fab in complex with HA of A/Hong Kong/1/1968 (H3N2; Protein
Data Bank [PDB] ID: 3SDY), the mutable sites were analyzed,
and HA mutations that contribute to destabilizing the epitope-
paratope interface without affecting HA stability (Experimental
Procedures) were predicted with atomic network interactions
and verified with physics-based modeling functions (Table 1).
Interestingly, the predicted escape mutations are a single
base-pair change away from the wild-type sequence, implying
potential for emergence of mutants that can escape antibody
detection and neutralization. Similarly, analysis to determine po-
tential escape mutations for H7 HA with a model of CR8020
docked with A/Shanghai/02/2013(H7N9) HA (PDB ID: 4LN3)
yielded 16 mutations at 7 mutable sites (Table 2).Cell HChanges in CR8020 Binding Residues May Be Driven by
Host Selection Pressure
Critically, the D19N CR8020 escape mutation is seen in one
of the circulating H7N9 outbreak viruses—A/Wuxi/1/2013
(H7N9)—suggesting that CR8020 is likely to be even less effec-
tive against this recent outbreak virus. Notably, this mutation has
not been previously observed in an Asian H7 virus. Out of the 612
H7 HA sequences available in the public database, 514 se-
quences (84%) contain D at position 19, and 98 sequences
(16%) contain N. The fact that HA can acquire stem mutations
begs the question whether these mutations are associated with
antigenic drift and immune escape. Until recently, the immuno-
dominance of the head region and the potency of antibodies
directed to the head yielded the concept of the canonical anti-
genic site model of HA, wherein a majority of the antigenic sites
are concentrated near the receptor binding site region (Soundar-
arajan et al., 2011; Gerhard et al., 1981; Wiley et al., 1981; Wilson
et al., 1981; Tsuchiya et al., 2001). However, recent vaccine clin-
ical studies have identified fusion-inhibiting stem binding bNAbs
in humans (Hardelid et al., 2010; Wei et al., 2010), antibodies
which are more broadly reactive. Additionally, analyses of B
cell epitopes from the Immune Epitope Database (http://www.
iedb.org) highlight the involvement of many HA2 stem residues,
including amino acids within the CR8020 epitope, as part of
many B cell epitopes (Figure S1 available online), indicating the
ability of the stem region to induce protective response. To
determine whether the D19N substitution is associated with anti-
genic drift, we considered accompanying changes within close
spatial and temporal proximity (Experimental Procedures); as
such, coevolving multiple mutations are probably indicative of
immune pressure exerted by host antibodies. Interestingly, res-
idues at 326 of HA1 and 160 of HA2 coevolve alongwith site 19 of
HA2 (Figures 1A–1D). The spatial proximity of these sites (Fig-
ure 1E) and their coevolution are consistent with the changes
observed at globular head B cell epitopes of HA (Shih et al.,
2007; Huang et al., 2009), implying stem antigenic evolution as
a result of host selection pressure. It must be noted that theost & Microbe 15, 644–651, May 14, 2014 ª2014 Elsevier Inc. 645
Table 2. Conservation of CR8020 Epitope Residues Computed across 612 Avian, Human, and Swine H7 HA Sequences and Predicted
Escape Mutations
HA2 Position (H3 Numbering) Consensus Alignment Details Number of Sequences SIN Score Predicted Escape Mutations
15 Glu Glu = 612 612 0.1015 W > H > T
16 Gly Gly = 612 612 0 W > Q
19 Asp Asn = 98, Asp = 514 612 0.0733
25 Arg Arg = 604, Lys = 8 612 0.3713
30 Gln Gln = 612 612 0.113 T > S
32 Glu Glu = 609, Lys = 3 612 0.1615
33 Gly Glu = 1, Gly = 611 612 0 L
34 Thr Asn = 1, Ile = 13, Thr = 598 612 0.1574
35 Ala Ala = 612 612 0.0459 W
36 Ala Ala = 612 612 0.0246 N > K > Q > R > S > D
38 Tyr His = 1, Tyr = 611 612 0.1735
146 Asp Asn = 6, Asp = 606 612 0.1509
150 Ala Ala = 330, Glu = 281, Gly = 1 612 0.0468 S
At each site, the predicted escape mutations are ranked (>) according to difference in free energy of binding. Mutation potential was measured by
applying SIN analysis on the crystal structure of A/Shanghai/02/2013 (H7N9) HA (PDB ID: 4LN3).
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CR8020 HA-Stem Epitope Can Accrue Escape Mutationschance occurrence of such coevolving sites in the stem region
where mutation rates are low is highly unlikely. In this context,
given the differences within the epitope for H7 in comparison
to H3, we anticipate that CR8020 would bind with low affinity,
a result which was verified experimentally. Whereas CR8020
bind with relatively high affinity to H3N2 strains such as A/Bris-
bane/10/2007 (IC50 of 3.36 nM) and A/Wyoming/3/2003 (IC50 of
0.06 nM), CR8020 did not show any noticeable binding to
A/Shanghai/02/2013, a representative H7N9 strain (Figure 1F).
Membrane May Sterically Hinder Binding of FcgR to Fc
within the Immune Complex
In addition to mutability of the epitope, on the basis of a recent
study by DiLillo et al. (2014), another factor that could limit the ef-
ficacy of bNAbs is the ability of the Fc region of the antibody to
effectively engage Fcg receptors in vivo. This study compared
the neutralization potential of head binding strain-specific HA an-
tibodies against stem binding bNAbs and found that, although
recognition of a ‘‘functional’’ epitope by the Fab arm of an anti-
body is pivotal for in vitro neutralization of the virus, the Fc-Fcg
receptor interaction and activation of antibody-dependent
cellular cytotoxicity (ADCC) was critical for the in vivo efficacy
of stem binding bNAbs. The Fc-Fcg receptor interaction is key
for regulating a host of innate and adaptive immune responses
in vivo. Antibodies can engage both activating and inhibitory
Fcg receptors as well asmediate killing of infected cells express-
ing HA by ADCC through interaction with activating Fcg recep-
tors (FcgRIIa and FcgRIIIa). Given that CR8020 targets a mem-
brane-proximal epitope (distance between base of the epitope
and membrane is approximately 14 A), we assessed whether
accessing the Fc tail of the CR8020-HA immune complex could
be an issue for the activating FcgRs. We evaluated the ability of
IgG CR8020 to engage FcgRs by building a molecular model of
the activation complex of FcgRIIa/RcgIIIa in the liganded state
(HA-CR8020 [IgG]) and, in turn, evaluated whether the viral or
cellular membrane could sterically hinder with the complex (Fig-
ures 2A–2D and Experimental Procedures). Both FcgRIIa and646 Cell Host & Microbe 15, 644–651, May 14, 2014 ª2014 Elsevier IFcgRIIIa were chosen for this modeling analysis because these
are the two common activating FcgRs in humans. Our structural
modeling shows that the membrane could sterically hinder the
formation of HA-CR8020-FcgRIIa and HA-CR8020-FcgRIIIa
ternary complexes (Figures 2A–2D). Because only one of the
activating FcgRs (FcgRIIIa) can potentially engage with
CR8020 (Figure 2B), this could possibly decrease the biological
activity and potentially the clinical efficacy of the antibody, given
that it is unclear which FcgR could dominate in vivo. A similar
modeling exercise performed on a different stem binding anti-
body, FI6, which binds higher up the stem region than
CR8020, demonstrated that the antibody may have a higher po-
tential to form the ternary complex with HA and both activating
receptors, FcgRIIa and FcgRIIIa. This is supported by the recent
study, which showed that PR8 virus-FI6 immune complex effi-
ciently binds to FcgRIIIa receptor (DiLillo et al., 2014). Further-
more, comparison of CR8020 to an antibody binding the trimeric
interface indicates that CR8020 is 10-fold less potent in elicit-
ing ADCC, measured as either concentration of onset or fold in-
duction (Figure 2E). Altogether, the experimental data combined
with the results of our modeling analyses indicate that location
and mutability of the epitope could play critical roles in deter-
mining the efficacy (or lack thereof) of CR8020 in the clinical
setting. In most preclinical virus-challenge experiments, dosing
of the antibody and the different strains of mice or ferrets is likely
measuring the ability of bNAbs to directly neutralize virus in vivo.
However, the recent study published with humanized mice ex-
pressing human FcgR suggests that Fc-FcgR interactions do
play a key role for at least two of the antistem bNAbs tested
and that at higher doses the in vivo protection can be indepen-
dent of the Fc-FcgR interaction (DiLillo et al., 2014). The Fc-
FcgR interaction requirement is well established for antibodies
that are used for other indications such as cancer. The results
of our analyses have practical implications for designing human
influenza clinical trials with bNAbs. Importantly, dosing regimen,
Fc engineering (for maximum affinity toward activating FcgRs),
and careful recruitment of patient population (keeping in mindnc.
Figure 1. Coevolution of Stem Residues and Measurement of CR8020 Binding to Various H3 and H7 Strains
(A–D) Coevolution between residues at 19 (HA2) and 326 (HA1) in H3 and H7 are shown in (A) and (B), respectively, and coevolution between residues at 19 (HA2)
and 160 (HA2) in H3 and H7 are shown in (C) and (D), respectively. In the alignment of 3,794 H3 sequences, the amino acid at position 19 of HA2 is conserved at
(legend continued on next page)
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CR8020 HA-Stem Epitope Can Accrue Escape MutationsFcgR polymorphism) need to be considered for clinical trial
design.
DISCUSSION
In our modeling of the activation complex, the oligomeric state of
FcgRIIa/FcgRIIa is kept as a monomer. Although it is believed
that FcgRIIa is constitutively present as a dimer on the cell sur-
face, the exact oligomeric state of FcgRIIa in the HA–IgG–
FcgRIIa complex has not been characterized. Furthermore,
modeling the activation complex with the crystallographic dimer
of FcgRIIa (PDB ID: 1FCG) does not alter the results of our anal-
ysis (data not shown).
DiLillo et al. (2014) suggest that conformational changes
induced in the Fc upon binding to the epitope could be the reason
for the difference in the ADCC potential of antistemmAbs in com-
parison toantiheadmAbs.Althoughouranalysisdoesnot take into
consideration Fc conformational changes, the Fc:FcgRmodeling
analysis suggests that steric hindrance could also be amajor fac-
tor in the differential FcgR-engaging capacities. Although DiLillo
et al. (2014) demonstrated differences between antihead mAbs
versus antistemmAbs in their ability to engage FcRs, our analysis
goes one step above to explain the striking differences in ADCC
mediated cell killing between two antistem bNAbs.
In light of the limitations of CR8020 identified by this study and
the importance of antiviral strategies against group 2 viruses
such as H3N2 and H7N9, bNAbs that target epitopes that are
accessible to immune complex assembly and less susceptible
to mutations are desired. Generally, epitopes that are closer to
the viral membrane harbor the most conserved and highly net-
worked epitopes with broad spectrum neutralizing potential;
however, location of the epitope could impose constraints on
accessibility. Conversely, epitopes on the globular head are
accessible but are susceptible to rapid antigenic drift (Figure S2).
Therefore, both epitope mutability and accessibility to immune
complex assembly are important attributes to factor in as one
evaluates suitable antibody candidates for clinical development.
Finally, we believe that these results have important ramifica-
tions for vaccine design. Multiple of the broadly neutralizing
antibodies originate from the Vh1-69 germline (Hwang et al.,
2014; Friesen et al., 2014). On the basis of the CR8020 data,
strategies focused on activation of this germlinemay not be ideal
to elicit full spectrum protection. Instead, activation of other
germlines, such as Vh3-30, may provide a better solution.98.91% as aspartic acid (83.93% conservation in 612 H7 sequences). When aspa
positions, referred as coevolution. A similar trend is observed in H7 subtype also. T
observed year-by-year in reported H3 and H7 sequences is demonstrated. A freq
that year, and a frequency of 1.0 means that all sequences from that year poss
temporal covariance of the coevolving residues.
(E) Location of the coevolving residues on the stem region of HA. The main chai
solvent accessible surface is shown in transparency. The side chain atoms of th
manuscript were rendered in PyMOL.
(F) The ability for CR8020 to bind to various influenza HA: A/Wyoming/3/2003 (H3N
2013 (H7N9; closed triangle). Also included was a BSA control (open triangle) coa
results are from a representative experiment. The full binding curve was comp
determined. CR8020 bound A/Wyoming/3/2003 (H3N2) very strongly with an app
pM). CR8020 bound A/Brisbane/10/2007 (H3N2) with an apparent Kd of 3.36 + 1.9
too weak in this assay to determine an apparent Kd.
See also Figure S1.
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Capturing Network of Protein Residues
The coordinates of A/X-31(H3N2) HA trimeric complex (PDB ID: 1HGG) and A/
Shanghai/02/2013 (H7N9) HA (PDB ID: 4LN3) were used to compute highly
networked epitope residues. For each case, various interresidue interatomic
contacts, including putative hydrogen bonds (including water-bridged ones),
disulfide bonds, pi bonds, polar interactions, salt bridges, and Van der Waals
interactions (nonhydrogen) occurring between pairs of residues were
computed as described previously (Soundararajan et al., 2011). The data
were assembled into an array of eight atomic interaction matrices. A weighted
sum of the eight atomic interaction matrices was computed in order to pro-
duce a single matrix that accounts for the strength of atomic interaction be-
tween residue pairs using weights derived from relative atomic interaction
energies (Soundararajan et al., 2011). The interresidue interaction network
calculated in this fashion generates a matrix that describes all the contacts
made between pairs of residues. For each element, i, j is the sum of the path
scores of all paths between residues i and j. The degree of networking score
for each residue was computed by summing across the rows of the matrix,
which corresponds to the extent of ‘‘networking’’ for each residue. The degree
of networking score was normalized (SIN score) with the maximum score for
the protein so that the scores varied from 0 (absence of any network) to 1
(most networked). From the previous study, residues with a SIN score ranging
from 0 to 0.2 are considered poorly networked, those with 0.2–0.5 are consid-
ered moderately networked, and those with >0.5 are highly networked.
Sequences, Amino Acid Variation, and Computation of Coevolving
Residues
17,921 sequences of theH3N2HAof human, avian, and swineH3N2strains iso-
latedbetween1934and2014weredownloaded fromhttp://fludb.org. Fromthis,
laboratory sequences,especiallymutants,wereexcluded. Ifmultiple sequences
were present for the same strain, then only the consensus was included. Addi-
tionally, only sequences that have complete coding regions including start and
stop codons were considered. The above procedure yielded 3,794 full-length
nonredundant sequences. A similar procedure when applied to human, avian
and swine H7N9 HA yielded 612 full-length nonredundant sequences. The
sequences were aligned with MUSCLE (Edgar, 2004). Then, we computed the
extent of variation at each position with the SNP tool at http://fludb.org. From
the alignment, intramolecular coevolving residues were computed with the
CAPS server with default parameters (http://bioinf.gen.tcd.ie/caps/home.html).
Computational Prediction of H3 and H7 Escape Mutations with
CR8020-HA Cocrystal Structures
Mutations detrimental to the epitope-paratope interface were first computed
with a built-in binding energy scoring function in Discovery Studio, which
performs amino acid scanning mutagenesis on a set of selected epitope resi-
dues and evaluates the effect of single point mutations on the binding affinity
of molecular partners. Then, to assess whether a mutation can impact the sta-
bility of HA, the interresidue interactions were computed upon modeling that
residue on HA. Amutation is considered to be harmless if it maintains the inter-
residue interaction network (determined by SIN) similar to that of the wild-type.rtic acid at 19 mutates to asparagine, mutations occur in structurally proximal
he frequency ofmutation (instances of deviance from the conserved residue) as
uency of 0.0 means the position was entirely conserved in all sequences from
essed a mutation at the given position. Mutation frequency charts show the
n of HA (PDB ID: 1HGG), colored in gray, is shown in cartoon format, and the
e coevolving residues are represented by spheres (red). All the images in the
2; open circle), A/Brisbane/10/2007 (H3N2; closed circle), and A/Shanghai/02/
ted instead of hemagglutinin in order to ensure no nonspecific binding. These
leted three times, and an apparent Kd expressed as an average + SD was
arent Kd of approximately 60 pm (individual measurements of 57, 59, and <80
7 nM. Binding to A/Shanghai/02/2013 (H7N9) and A/Anhui/1/2013 (H7N9) was
nc.
Figure 2. Modeling the HA-CR8020-FcgRIIa/HA-CR8020-FcgRIIIa Activation Complex and Measurement of Cell Killing by Anti-influenza
Antibodies
(A–D) The CR8020-HA complex crystal structure (PDB ID: 3SDY) was used to model the IgG-HA interaction. Given the different orientations of the two Fab
domains (from here onward referred to as Fab and Fab’) with respect to the Fc, as observed in the human IgG1 X-ray crystal structure (PDB ID: 1HZH), two
different IgG-HA models were constructed (Experimental Procedures) where, in one case, Fab was docked against the H3, and, in the other, Fab’ was docked
against the H3 (A and C). Then, FcgRIIa and FcgRIIIa, represented by solvent accessible surface and colored in gray and magenta, respectively, were docked
against Fc in a fashion (Experimental Procedures) that mimics their interaction seen in the Fc:FcgRIIa (PDB ID: 3RY6) and Fc:FcgRIIIa (PDB ID: 3AY4) cocrystal
structures (B and D). In the first model, the FcgRIIIa is proximal to the membrane, which could cause steric hindrance; interaction with FcgRIIa is sterically
hindered by the membrane (B), whereas, in the second model, the Fab domain is oriented too close to the viral membrane, which suggests that the model is not
plausible (C and D).
(E) The ability for CR8020 (closed square) and an antibody targeting the trimeric interface (closed triangle) to activate FcRIIIa in the presence of influenza-infected
A549 cells wasmeasured. A IgG binding to an irrelevant antigen (closed diamond) showed no activity in this assay. Results are shown as an average + SEM (n=3).
See also Figure S2.
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CR8020 HA-Stem Epitope Can Accrue Escape MutationsModeling the HA-IgG-FcgRIIa/HA-IgG-FcgRIIIa Ternary Activation
Complex
Themodelingwas carried out in two steps. In step one, the Fab arm of a human
IgG 1 (from X-ray crystal structure; PDB ID: 1HZH) was superposed onto the
CR8020-HA cocrystal structure (PDB ID: 3SDY). Because Fab and Fab’ areCell Hpositioned differently relative to the Fc, two different models of IgG-HA inter-
actions were obtained. In step two, the FcgRIIa receptor from PDB ID 3RY6
and FcgRIIIa receptor from PDB ID 3AY4 were docked against the Fc by su-
perposing the Fc:FcgRIIa/Fc:FcgRIIIa cocrystal structure on the Fc region of
the IgG-HA complex. A similar procedure was carried out in order to obtainost & Microbe 15, 644–651, May 14, 2014 ª2014 Elsevier Inc. 649
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CR8020 HA-Stem Epitope Can Accrue Escape Mutationsthe HA-FI6-FcgRIIa/HA-FI6-FcgRIIIa ternary activation complex. Structural
alignment and visualization were performed with PyMOL.
ELISA Binding Assays
Recombinant hemagglutinin (Protein Sciences) was coated on 96-well micro-
titer plates (Immuno Maxisorp, Nunc) and blocked with 5% Blotto (Santa Cruz
Biotechnology) in 13 PBS. Serially diluted CR8020 antibody, whose sequence
is described in patent PCT/EP2010/056217 (Throsby et al., 2010), was added,
and binding detected with horseradish-peroxidase-conjugated goat anti-
human IgG (Fc-specific; Bethyl Laboratories) followed by development with
3,3,5,5-tetramethylbenzidine solution (KPL). The absorbance at 450 nm was
measured with a Spectramax plate reader (Molecular Devices), and data
were analyzed with Softmax.
Measurement of Antibody-Dependent Cellular Cytotoxicity
The ability for CR8020 and an antibody targeting the trimeric interface were
tested for their ability to mediate FcgammaRIIIa engagement. Target cells
were created by infecting A549 cells with A/Victoria/3/75 (H3N2) at a multiplic-
ity of infection 1.0 for 18 hr, after which cells are seeded into a white 96-well
plate. Control experiments employing fluorescence-activated cell sorting indi-
cated that both antibodies bound to infected cells. The ADCC Reporter Assay
from Promega was used to assess killing with an assay control of an anti-CD20
mAb added to WIL2-S cells. Dilutions of ‘‘test’’ and ‘‘control’’ mAbs were
added to target cells, and engineered effector cells (Jurkat T cells transfected
with CD16 (V/V 158 variant) and NFAT-firefly luciferase gene) are added to
wells and allowed to incubate for 6 hr at 37C. Then, Bio-Glo Luciferase
substrate solution was added to wells in order to measure activation of
FcgammaRIIIa and results read on a luminometer.SUPPLEMENTAL INFORMATION
Supplemental Information contains two figures and can be found with this
article online at http://dx.doi.org/10.1016/j.chom.2014.04.009.
AUTHOR CONTRIBUTIONS
K.T., V. Subramanian, V. Sasisekharan, and R.S. conceptualized and designed
the study. K.T. and D.C. implemented the computational modeling analysis.
K.T. and V. Sasisekharan performed the structural modeling. V. Subramanian
and R.S. designed the ELISA and ADCC assays to measure HA binding and
FcR-mediated cell killing. K.T., V. Subramanian, V. Sasisekharan, and R.S.
wrote the manuscript.
ACKNOWLEDGMENTS
This work was funded in part by a National Institutes of Health Merit Award
(R37 GM057073-13), National Research Foundation-supported Interdisci-
plinary Research Group in Infectious Diseases of SMART (Singapore MIT Alli-
ance for Research and Technology), and the Skolkovo Foundation-supported
Infectious Diseases Center at MIT.
Received: February 25, 2014
Revised: April 2, 2014
Accepted: April 11, 2014
Published: May 14, 2014
REFERENCES
Corti, D., Voss, J., Gamblin, S.J., Codoni, G., Macagno, A., Jarrossay, D.,
Vachieri, S.G., Pinna, D., Minola, A., Vanzetta, F., et al. (2011). A neutralizing
antibody selected from plasma cells that binds to group 1 and group 2 influ-
enza A hemagglutinins. Science 333, 850–856.
DiLillo, D.J., Tan, G.S., Palese, P., and Ravetch, J.V. (2014). Broadly neutral-
izing hemagglutinin stalk-specific antibodies require FcgR interactions for pro-
tection against influenza virus in vivo. Nat. Med. 20, 143–151.650 Cell Host & Microbe 15, 644–651, May 14, 2014 ª2014 Elsevier IDreyfus, C., Ekiert, D.C., and Wilson, I.A. (2013). Structure of a classical
broadly neutralizing stem antibody in complex with a pandemic H2 influenza
virus hemagglutinin. J. Virol. 87, 7149–7154.
Edgar, R.C. (2004). MUSCLE: multiple sequence alignment with high accuracy
and high throughput. Nucleic Acids Res. 32, 1792–1797.
Ekiert, D.C., Friesen, R.H., Bhabha, G., Kwaks, T., Jongeneelen, M., Yu, W.,
Ophorst, C., Cox, F., Korse, H.J., Brandenburg, B., et al. (2011). A highly
conserved neutralizing epitope on group 2 influenza A viruses. Science 333,
843–850.
Friesen, R.H., Lee, P.S., Stoop, E.J., Hoffman, R.M., Ekiert, D.C., Bhabha, G.,
Yu, W., Juraszek, J., Koudstaal, W., Jongeneelen, M., et al. (2014). A common
solution to group 2 influenza virus neutralization. Proc. Natl. Acad. Sci. USA
111, 445–450.
Gao, R., Cao, B., Hu, Y., Feng, Z., Wang, D., Hu, W., Chen, J., Jie, Z., Qiu, H.,
Xu, K., et al. (2013). Human infection with a novel avian-origin influenza A
(H7N9) virus. N. Engl. J. Med. 368, 1888–1897.
Gerhard, W., Yewdell, J., Frankel, M.E., and Webster, R. (1981). Antigenic
structure of influenza virus haemagglutinin defined by hybridoma antibodies.
Nature 290, 713–717.
Graves, P.N., Schulman, J.L., Young, J.F., and Palese, P. (1983). Preparation
of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin:
unmasking of cross-reactive HA2 determinants. Virology 126, 106–116.
Hai, R., Schmolke, M., Leyva-Grado, V.H., Thangavel, R.R., Margine, I., Jaffe,
E.L., Krammer, F., Solo´rzano, A., Garcı´a-Sastre, A., Palese, P., and Bouvier,
N.M. (2013). Influenza A(H7N9) virus gains neuraminidase inhibitor resistance
without loss of in vivo virulence or transmissibility. Nat Commun 4, 2854.
Hardelid, P., Andrews, N.J., Hoschler, K., Stanford, E., Baguelin, M., Waight,
P.A., Zambon, M., and Miller, E. (2010). Assessment of baseline age-specific
antibody prevalence and incidence of infection to novel influenza A/H1N1
2009. Health Technol. Assess. 14, 115–192.
Huang, J.W., King, C.C., and Yang, J.M. (2009). Co-evolution positions and
rules for antigenic variants of human influenza A/H3N2 viruses. BMC
Bioinformatics 10 (Suppl 1 ), S41.
Hwang, K.K., Trama, A.M., Kozink, D.M., Chen, X.,Wiehe, K., Cooper, A.J., Xia,
S.M., Wang, M., Marshall, D.J., Whitesides, J., et al. (2014). IGHV1-69 B cell
chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis
Cvirus antigens aswell as intestinal commensal bacteria. PLoSONE9, e90725.
Iwane, M.K., Edwards, K.M., Szilagyi, P.G., Walker, F.J., Griffin, M.R.,
Weinberg, G.A., Coulen, C., Poehling, K.A., Shone, L.P., Balter, S., et al.;
New Vaccine Surveillance Network (2004). Population-based surveillance for
hospitalizations associated with respiratory syncytial virus, influenza virus,
and parainfluenza viruses among young children. Pediatrics 113, 1758–1764.
Jansen, A.G., Sanders, E.A., Hoes, A.W., van Loon, A.M., and Hak, E. (2007).
Influenza- and respiratory syncytial virus-associated mortality and hospitalisa-
tions. Eur. Respir. J. 30, 1158–1166.
Kawaoka, Y., Krauss, S., andWebster, R.G. (1989). Avian-to-human transmis-
sion of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics.
J. Virol. 63, 4603–4608.
Kwong, P.D., Mascola, J.R., and Nabel, G.J. (2011). Rational design of
vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb
Perspect Med 1, a007278.
Muster, T., Steindl, F., Purtscher, M., Trkola, A., Klima, A., Himmler, G., Ru¨ker,
F., and Katinger, H. (1993). A conserved neutralizing epitope on gp41 of human
immunodeficiency virus type 1. J. Virol. 67, 6642–6647.
Nabel, G.J. (2012). Rational design of vaccines for AIDS and influenza. Trans.
Am. Clin. Climatol. Assoc. 123, 9–15, discussion 15–16.
Okuno, Y., Isegawa, Y., Sasao, F., and Ueda, S. (1993). A common neutralizing
epitope conserved between the hemagglutinins of influenza A virus H1 and H2
strains. J. Virol. 67, 2552–2558.
Pejchal, R., Walker, L.M., Stanfield, R.L., Phogat, S.K., Koff, W.C., Poignard,
P., Burton, D.R., and Wilson, I.A. (2010). Structure and function of broadly
reactive antibody PG16 reveal an H3 subdomain that mediates potent neutral-
ization of HIV-1. Proc. Natl. Acad. Sci. USA 107, 11483–11488.nc.
Cell Host & Microbe
CR8020 HA-Stem Epitope Can Accrue Escape MutationsPejchal, R., Doores, K.J., Walker, L.M., Khayat, R., Huang, P.S., Wang, S.K.,
Stanfield, R.L., Julien, J.P., Ramos, A., Crispin, M., et al. (2011). A potent
and broad neutralizing antibody recognizes and penetrates the HIV glycan
shield. Science 334, 1097–1103.
Scheid, J.F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T.Y.,
Pietzsch, J., Fenyo, D., Abadir, A., Velinzon, K., et al. (2011). Sequence and
structural convergence of broad and potent HIV antibodies that mimic CD4
binding. Science 333, 1633–1637.
Shih, A.C., Hsiao, T.C., Ho,M.S., and Li,W.H. (2007). Simultaneous amino acid
substitutions at antigenic sites drive influenza A hemagglutinin evolution. Proc.
Natl. Acad. Sci. USA 104, 6283–6288.
Soundararajan, V., Zheng, S., Patel, N., Warnock, K., Raman, R., Wilson, I.A.,
Raguram, S., Sasisekharan, V., and Sasisekharan, R. (2011). Networks link
antigenic and receptor-binding sites of influenza hemagglutinin: mechanistic
insight into fitter strain propagation. Sci Rep 1, 200.
Steel, J., Lowen, A.C., Wang, T.T., Yondola, M., Gao, Q., Haye, K., Garcı´a-
Sastre, A., and Palese, P. (2010). Influenza virus vaccine based on the
conserved hemagglutinin stalk domain. MBio 1, e00018–e10.
Sui, J., Hwang, W.C., Perez, S., Wei, G., Aird, D., Chen, L.M., Santelli, E., Stec,
B., Cadwell, G., Ali, M., et al. (2009). Structural and functional bases for broad-
spectrum neutralization of avian and human influenza A viruses. Nat. Struct.
Mol. Biol. 16, 265–273.
Throsby, M., Friesen, R.H.E., Kwaks, T.H.J., and Jongeneelen, M.A.C. (2010).
Human binding molecules capable of neutralizing influenza virus H3N2 and
uses thereof. http://www.google.com/patents/US8470327.
Tsuchiya, E., Sugawara, K., Hongo, S., Matsuzaki, Y., Muraki, Y., Li, Z.N., and
Nakamura, K. (2001). Antigenic structure of the haemagglutinin of human
influenza A/H2N2 virus. J. Gen. Virol. 82, 2475–2484.Cell HWei, C.J., Boyington, J.C., McTamney, P.M., Kong, W.P., Pearce, M.B., Xu, L.,
Andersen, H., Rao, S., Tumpey, T.M., Yang, Z.Y., and Nabel, G.J. (2010).
Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.
Science 329, 1060–1064.
Wiley, D.C., Wilson, I.A., and Skehel, J.J. (1981). Structural identification of
the antibody-binding sites of Hong Kong influenza haemagglutinin and their
involvement in antigenic variation. Nature 289, 373–378.
Wilson, I.A., Skehel, J.J., and Wiley, D.C. (1981). Structure of the haemagglu-
tinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 289,
366–373.
Wu, X., Yang, Z.Y., Li, Y., Hogerkorp, C.M., Schief, W.R., Seaman, M.S., Zhou,
T., Schmidt, S.D., Wu, L., Xu, L., et al. (2010). Rational design of envelope
identifies broadly neutralizing human monoclonal antibodies to HIV-1.
Science 329, 856–861.
Zwick, M.B., Labrijn, A.F., Wang, M., Spenlehauer, C., Saphire, E.O., Binley,
J.M., Moore, J.P., Stiegler, G., Katinger, H., Burton, D.R., and Parren, P.W.
(2001). Broadly neutralizing antibodies targeted to the membrane-proximal
external region of human immunodeficiency virus type 1 glycoprotein gp41.
J. Virol. 75, 10892–10905.
Zwick, M.B., Parren, P.W., Saphire, E.O., Church, S., Wang, M., Scott, J.K.,
Dawson, P.E., Wilson, I.A., and Burton, D.R. (2003). Molecular features of
the broadly neutralizing immunoglobulin G1 b12 required for recognition of hu-
man immunodeficiency virus type 1 gp120. J. Virol. 77, 5863–5876.
Note Added in Proof
Since the submission of this manuscript, one of the CR8020 clinical
trials (NCT01992276; http://clinicaltrials.gov/ct2/show/NCT01992276?
term=cr8020&rank=4) was withdrawn due to "preliminary efficacy results
from an influenza challenge trial".ost & Microbe 15, 644–651, May 14, 2014 ª2014 Elsevier Inc. 651
